Đăng xuất
SERETIDE Evohaler DC is for inhalation only.
Patients should be made aware that SERETIDE Evohaler DC must be used regularly for optimum benefit, even when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the strength of SERETIDE they are receiving remains optimal and is only changed on medical advice.
ASTHMA (Reversible Obstructive Airways Disease): The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Where the control of symptoms is maintained with twice daily SERETIDE, titration to the lowest effective dose could include SERETIDE given once daily.
Patients should be given the strength of SERETIDE containing the appropriate fluticasone propionate dosage for the severity of their disease.
If a patient is inadequately controlled on inhaled corticosteroid therapy alone, substitution with SERETIDE at a therapeutically equivalent corticosteroid dose may result in an improvement in asthma control. For patients whose asthma control is acceptable on inhaled corticosteroid therapy alone, substitution with SERETIDE may permit a reduction in corticosteroid dose while maintaining asthma control. For further information, refer to Pharmacology: Pharmacodynamics under Actions.
Recommended Doses: Adults and adolescents 12 years and older: Two inhalations of 25 micrograms salmeterol and 50 micrograms fluticasone propionate twice daily; or Two inhalations of 25 micrograms salmeterol and 125 micrograms fluticasone propionate twice daily; or Two inhalations of 25 micrograms salmeterol and 250 micrograms fluticasone propionate twice daily.
The maximum recommended dosage for adults and adolescents 12 years and older is 500/50 twice daily
Children 4 years and older: Two inhalations of 25 micrograms salmeterol and 50 micrograms fluticasone propionate twice daily.
The maximum licensed dose of fluticasone propionate delivered by Seretide Evohaler DC in children is 100 micrograms twice daily.
There are no data available for use of SERETIDE in children aged under 4 years.
Chronic Obstructive Pulmonary Disease (COPD): For adult patients the recommended dose is two inhalations 25/125 micrograms to 25/250 micrograms salmeterol/fluticasone propionate twice daily. At a dose of 50/500 micrograms twice daily, SERETIDE has been shown to reduce all-cause mortality (see Pharmacology: Pharmacodynamics under Actions).
Special patient groups: There is no need to adjust the dose in elderly patients or in those with renal or hepatic impairment.
